Today on Drug Discovery & Development
From Novartis to Pfizer: A closer look at novel cell and gene therapy pricing and reimbursement strategies
Cell and gene therapies are upending the treatment of a growing number of diseases by addressing the underlying causes of genetic disorders. Yet the high costs associated with these therapies, sometimes costing multiple millions of dollars for a single treatment, pose significant challenges for patients, payers and healthcare systems. To address this matter, a growing…
With prices topping $4 million, high stakes define cell and gene therapy landscape
Cell and gene therapies often promise unparalleled treatment options for patients, but sometimes those benefits come at an extraordinary cost. The therapy class is responsible for the world’s most expensive drugs, including the recently FDA-approved gene therapy, Libmeldy, with a wholesale acquisition cost of $4.25 million. The prior record holder, Hemgenix, had a $3.5 million…
Drug Discovery and Development See More >
New pharma and biotech manufacturing facilities and expansions announced worldwide for 2024
[Updated April 23, 2024] In the face of rising R&D costs and growing pricing pressures from payers, the pharma and biotech sectors continue to transform to adapt to an evolving landscape. While workforce reductions persist in 2024 for some companies, major players like AbbVie, AGC Biologics, Amgen, Novartis and Thermo Fisher Scientific are demonstrating confidence…
Sponsored Content See More >
Innovations in Baculovirus–Insect Cell Expression SystemsThe baculovirus–insect cell expression system—insect cells used in conjunction with the baculovirus expression vector system (BEVS)—remains a crucial technology for…
Patient Training is Broken – And Everyone is Paying For ItNoble International is working with Pharma and Specialty Pharmacy to fix the problem. The report, “The Current Paradigm for Biologic…
Noble Leads with its User-Centered Design StrategyBy Tim McLeroy, Executive Director of Marketing and Patient Services, Noble International At Noble, the patient journey drives everything we…
Using Real-World Data to Address COVID-19By Cheryl Reifsnyder, PhD As a leading provider of data and advanced analytics, Veradigm understands the critical role real-world data…
Discovering Antigen-specific Monoclonal Antibodies using Single B Cell ScreeningIntroduction Since the approval of Orthoclone OKT3 in 1986, more than 100 monoclonal antibodies (mAbs) have been approved by the…
A new way to access scientific papers?Losing university access doesn’t mean losing access to articles anymore By DeepDyve Digital Library Team Many researchers are surprised to…
These are not fireworks: The objective truthBy Jan Barghaan, Strategic Marketing Manager Life Science, Olympus Europa No, not fireworks — it’s actually a single colony of…
AI technology automates tedious cell culture work and analysesBy Joanna Hawryluk, PhD, Product Manager, Olympus Life Science Since the early 20th century, cell culture has been considered the…
What is Human AB serum?By Trevor Smith, MS MBA, Product Manager, Immune Cells Human AB Serum is a staple in the biological research field,…
Resolving binding kinetics on a microplate readerWith a better understanding of the causes and mechanisms behind diseases arises a need for new treatment options and drugs…
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Micro 3D Printing Advances Biomarker DetectionResearchers in China have used Projection Micro Stereolithography (PµSL) to improve the fabrication of micropillar array electrodes (µAEs) for the…
Genomics/Proteomics See More >
Study combines biomimetic AI, digital twins and multiomics to unveil potential genetic drivers of endometriosis
Endometriosis, a condition where endometrial tissue grows outside the uterus, has a strong genetic underpinning. A new study published in the Journal of Molecular Diagnostics sheds light on this connection. Researchers from a team including Genzeva, LumaGene, RYLTI Biopharma, Brigham & Women’s Hospital of Harvard University and QIAGEN Digital Insights used a unique approach in…
Unleashing a new frontier: The power of germline clinico-genomic data to drive therapeutic development
NVIDIA expands BioNeMo platform with new foundation models and microservices for AI-powered Drug Discovery
Navigating the cancer progression pathway with liquid biopsy
Microsoft and 1910 Genetics: AI-powered partnership targets billion-dollar savings and growth in drug discovery
Infectious Disease See More >
Public vs. private: Who’s leading the charge in H5N1 preparedness?
The recent emergence of H5N1 avian influenza in humans and many other animals has intensified global efforts to prepare for a potential pandemic. Public health agencies and international organizations are collaborating with pharmaceutical companies and academic institutions to develop vaccines, treatments, and strategies to mitigate the impact of an outbreak. The CDC, for instance, has…
Best-selling pharmaceuticals of 2023 reveal a shift in pharma landscape
Lumen Bioscience cracks the code on spirulina as a biologics factory for c. diff, metabolic disease and more
Vaccine mega-trials: Rare behemoths in the vaccine trial landscape
Biden names 31 tech hubs: Here are 10 relevant to pharma and biotech
Oncology See More >
FDA approves pair of therapies for rare pediatric cancers: Novartis’ Lutathera and Day One’s Ojemda
The FDA has signed off on two novel therapies targeting rare pediatric cancers. Novartis’ Lutathera targets aggressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in children 12 and up, while Day One Biopharma’s Ojemda (tovorafenib) tackles treatment-resistant BRAF-mutated relapsed or refractory pediatric low-grade glioma (pLGG) with a BRAF fusion or rearrangement, or BRAF V600 mutation These approvals offer…
